Cargando…

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs

Introduction: Acromegaly is a rare, serious endocrine disorder characterized by excess growth hormone (GH) secretion by a pituitary adenoma and overproduction of insulin-like growth factor I (IGF-I). Transsphenoidal surgery is the treatment of choice, although many patients require additional interv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gadelha, Mônica, Bex, Marie, Colao, Annamaria, Pedroza García, Elier Mitsael, Poiana, Catalina, Jimenez-Sanchez, Marisela, Yener, Serkan, Mukherjee, Rishav, Bartalotta, Amy, Maamari, Ricardo, Raverot, Gérald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008501/ https://www.ncbi.nlm.nih.gov/pubmed/32117045 http://dx.doi.org/10.3389/fendo.2019.00931

Ejemplares similares

SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study
por: Gadelha, Mônica, et al.
Publicado: (2019)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
por: Colao, Annamaria, et al.
Publicado: (2020)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells
por: Rossi, Valentina, et al.
Publicado: (2019)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
por: Marques, Nelma Veronica, et al.
Publicado: (2023)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
por: Bronstein, Marcello D., et al.
Publicado: (2016)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
por: Puglisi, Soraya, et al.
Publicado: (2020)

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience
por: Gadelha, Mônica, et al.
Publicado: (2023)

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Erratum to: Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

Vertebral Fractures in Acromegaly: A Systematic Review
por: Sorohan, Madalina Cristina, et al.
Publicado: (2022)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression
por: Mizuno, Tomoko, et al.
Publicado: (2021)

Pasireotide—a novel somatostatin receptor ligand after 20 years of use
por: Bolanowski, Marek, et al.
Publicado: (2022)

MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands
por: Henriques, Daniel G., et al.
Publicado: (2022)

Disposition Index in Active Acromegaly
por: Niculescu, Dan Alexandru, et al.
Publicado: (2019)

Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly
por: Amarawardena, W K M G, et al.
Publicado: (2017)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations
por: Colao, Annamaria, et al.
Publicado: (2013)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
por: Lasolle, Hélène, et al.
Publicado: (2019)

Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly
por: Fukunaga, Kensaku, et al.
Publicado: (2020)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mcl3bfj5vrf7hvaqik4rpr2u9m